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LETTER
Endothelial progenitor cells are cellular
hubs essential for neoangiogenesis of
certain aggressive adenocarcinomas
and metastatic transition but
not adenomas
Purhonen et al. (1) have refuted the data published in 50
reports (2, 3), neglecting to quote key articles or utilize rele-
vant models, and have drawn unsubstantiated conclusions
about the contribution of endothelial progenitor cells (EPCs)
to tumor angiogenesis that are not supported by their non-
quantitative data and superficially executed experiments.
Their study (1) is f lawed in experimental design and data in-
terpretation. For example, they do not cite their own publica-
tion demonstrating the existence of VEGFR2 EPCs (4) and
neglect mentioning clinical validation (5, 6) and acknowledg-
ing mouse genetic models (2, 3), which provide convincing
evidence for functional incorporation of EPCs into neoves-
sels. Every figure lacks stereoconfocal-microscopic quantifica-
tion of vessels that are presented as poorly defined longitudi-
nal–linear streaks. Plasma VEGF-A levels were not measured
in vivo in mice treated with VEGF-A, questioning their low
level of VEGFR2 EPC detection (3). Indeed, their FACS
analysis is inaccurate because of (i) unconvincing CD31/VE-
cadherin/VEGFR2 expression detected on MS-1 endothelium
used as positive control and (ii) failure to show long-term
marrow engraftment of donor-derived hematopoietic and au-
thentic VEGFR2LacZ colony-forming EPCs. APCmin
mice develop only obstructive adenomas, rather than adeno-
carcinomas; therefore, it is an inappropriate model to study
EPC incorporation, as Spring et al. (7) (not quoted) demon-
strate that EPCs do not contribute to adenomas but contrib-
ute only to carcinomas/metastatic tumors. In the parabiotic
model, wild-type EPCs compete with GPF EPCs, which un-
derestimates EPC recruitment. Finally, study of 6-month-old
VEGF-A-loaded Matrigel plugs in mice is impossible because
Matrigel plugs are degraded within 2 months, particularly
when VEGF-A by itself does not induce neoangiogenesis. No
quantification of patent vessels in Matrigel plugs was pro-
vided. This article fails to disprove the established role of
EPCs in supporting neoangiogenesis in certain tumors (3, 5)
and metastatic transition (2).
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